FDA Approval of Ziftomenib (KOMET-001) in NPM1 mut Acute Myeloid Leukemia (AML) – Dr. Eunice Wang

In this episode of the Oncology Brothers podcast, we dived into the exciting world of cancer treatment with a focus on the recent FDA approval of Ziftomenib for relapsed refractory NPM1 mutated acute myeloid leukemia (AML). 

We were joined by Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center as our guest. Dr. Wang shared insights from the KOMET-001 study, detailing the study design, efficacy, and safety profile of Ziftomenib. With a response rate of nearly 30% and significant overall survival benefits for patients, this new treatment option is a promising step forward in managing heavily pretreated AML.

Key topics covered in this episode included:

• The mechanism of action of Ziftomenib as a menin inhibitor
• Study findings from KOMET-001 and patient response rates
• Management of side effects, including differentiation syndrome and QTc prolongation
• Comparison with other menin inhibitors like Revumenib
• Future directions for combination therapies and sequencing of treatments

Whether you're a healthcare professional, a patient, or simply interested in the latest advancements in cancer therapy, this episode is packed with valuable information. 

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Don't forget to like, subscribe, and check out our other episodes for more insights into FDA approvals, toxicity management, and practice-changing conference highlights.

#Ziftomenib #MeninInhibitor #AML #NPM1 #Leukemia #FDAapproval #OncologyBrothers